Generics Bulletin is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Multiple Myeloma: A Growth Market Set To Shrink As Revlimid Generics Hit

Executive Summary

Despite several new entrants to the multiple myeloma market, Datamonitor Healthcare forecasts that drug sales between 2017 and 2026 will peak in 2022 when Revlimid generics hit the market. J&J's Darzalex will become the new best-seller, but generate a fraction of Revlimid's sales.


Related Content

Keeping Track: Poteligeo, Onpattro, Galafold And Annovera Approved; Selinexor Submitted
New Mechanism And Oral Activity Underline Selinexor's Role In Multiple Myeloma
Interview: Amgen's BiTE Platform Becomes A Feast As More Molecules Enter The Clinic
Celgene Focuses On Deals, Pipeline As Post-Revlimid Future Draws Closer
GSK's Oncology R&D Head: GSK2857916 'Proves We're Still Here And Serious'
Celgene Diversifying Beyond Myeloma Backbone Revlimid
Multiple Myeloma Market Snapshot: New Drugs And Big Changes
Amgen buying Onyx for $10.4 billion to be bigger player in cancer therapies


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts